Clinical Trial Search

Primary: Clinically Significant Treatment Emergent Events — 37; 30; 22; 20 Number of patients

Primary: Number of Micturations Per 24 Hour Period — 8.78; 9.19; 8.00; 8.94 Number of micturations per 24 hours — p=0.53

Primary: Pharmacokinetics: Area Under the Concentration Versus Time Curve From Time Zero to Infinity [AUC(0-∞)] of Cephalexin Following a Single Dose — 29.539; 35.857…

Primary: Mean Change in Visual Acuity — 15.0; 5.6 letters — p=0.02

Primary: Binocular Distance Corrected Visual Acuity (logMAR) - Intermediate (60 cm) — 0.13; 0.09 logMAR

Primary: Pharmacokinetics: Area Under the Concentration Versus Time Curve of Cephalexin From Time Zero to Infinity [AUC(0-∞)] of Cephalexin Following a Single Dose — 19.102…

Primary: Pharmacokinetic Parameters of Avibactam and Ceftazidime for Cohort 1 and 2: AUC — 35140; 219100; 33590; 212400 h*ng/mL

Primary: Change From Baseline in Area Under the Curve (AUC) Glucose at Week 2 — -794.2; 482.7 (mg/dL)*min — p=0.03

Primary: Proportion (Percentage) of Androxal Treated Subjects With Testosterone in the Normal Range — 78.8 Percentage of Subjects

Primary: Frequency of FI Episodes — 79; 86 percentage of participants

Primary: Combined Failure of Bacteriological Cure and Relapse Within One Year of Completion of Therapy as Defined by Culture Using Solid Media (Lowenstein-Jensen - LJ). — 43; 78…

Primary: Percentage of Participants With Adverse Events (AEs) and Serious AEs (SAEs) Related to Bevacizumab, Death, and AEs of Special Interest (AESIs) — 95.4; 57.6; 64.2; 29.7…

Primary: Isometric Lumbar Extension Muscular Strength at 11 Weeks — 310.2; 282.7 Nm — p=0.001

Primary: Oswestry Disability Index (ODI) at 12 Weeks — 35.95; 33.54; 37.83 units on a scale

Primary: Geometric Mean Concentrations (GMC) for Diphtheria and Tetanus Antigens — 9.3; 9.8; 9.4; 10.3 IU/mL